[HTML][HTML] Reduced erythrocyte membrane polyunsaturated fatty acid levels indicate diminished treatment response in patients with multi-versus first-episode …

N Li, P Yang, M Tang, Y Liu, W Guo, B Lang, J Wang… - Schizophrenia, 2022 - nature.com
Antipsychotic effects seem to decrease in relapsed schizophrenia patients and the
underlying mechanisms remain to be elucidated. Based on the essential role of …

[HTML][HTML] Association of polygenic risk for major psychiatric illness with subcortical volumes and white matter integrity in UK Biobank

LM Reus, X Shen, J Gibson, E Wigmore, L Ligthart… - Scientific reports, 2017 - nature.com
Major depressive disorder (MDD), schizophrenia (SCZ) and bipolar disorder (BP) are
common, disabling and heritable psychiatric diseases with a complex overlapping polygenic …

Efficacy of adjunctive infliximab vs. placebo in the treatment of anhedonia in bipolar I/II depression

Y Lee, RB Mansur, E Brietzke, NE Carmona… - Brain, behavior, and …, 2020 - Elsevier
We investigated the efficacy of tumour necrosis factor (TNF)-α antagonist infliximab on a
measure of anhedonia amongst individuals with bipolar I/II depression (ClinicalTrials. gov …

Brain eicosapentaenoic acid metabolism as a lead for novel therapeutics in major depression

RP Bazinet, AH Metherel, CT Chen, SR Shaikh… - Brain, behavior, and …, 2020 - Elsevier
The results of several meta-analyses suggest that eicosapentaenoic acid (EPA)
supplementation is therapeutic in managing the symptoms of major depression. It was …

[HTML][HTML] Brain kynurenine and BH4 pathways: relevance to the pathophysiology and treatment of inflammation-driven depressive symptoms

S Vancassel, L Capuron, N Castanon - Frontiers in Neuroscience, 2018 - frontiersin.org
The prevalence of depressive disorders is growing worldwide, notably due to stagnation in
the development of drugs with greater antidepressant efficacy, the continuous large …

On the transdiagnostic nature of peripheral biomarkers in major psychiatric disorders: a systematic review

JV Pinto, TC Moulin, OB Amaral - Neuroscience & Biobehavioral Reviews, 2017 - Elsevier
The search for biomarkers has been a leading endeavor in biological psychiatry. To analyze
its evolution over the years, we performed a systematic review to evaluate (a) the most …

[HTML][HTML] Effects of n-3 polyunsaturated fatty acid supplementation in the prevention and treatment of depressive disorders—a systematic review and meta-analysis

M Wolters, A von der Haar, AK Baalmann, M Wellbrock… - Nutrients, 2021 - mdpi.com
N-3 polyunsaturated fatty acids (PUFAs) have been suggested to affect depressive
disorders. This review aims to determine the effect of n-3 PUFAs on depressive symptoms in …

[HTML][HTML] Long chain omega-3 polyunsaturated fatty acid supplementation alleviates doxorubicin-induced depressive-like behaviors and neurotoxicity in rats …

YQ Wu, RL Dang, MM Tang, HL Cai, HD Li, DH Liao… - Nutrients, 2016 - mdpi.com
Doxorubicin (DOX) is a chemotherapeutic agent widely used in human malignancies. Its
long-term use can cause neurobiological side-effects associated with depression. Omega-3 …

[HTML][HTML] Nutritional neuroscience as mainstream of psychiatry: the evidence-based treatment guidelines for using omega-3 fatty acids as a new treatment for …

JPC Chang, KP Su - Clinical Psychopharmacology and …, 2020 - ncbi.nlm.nih.gov
Omega-3 polyunsaturated fatty acids (or omega-3 PUFAs, n-3 PUFAs) are essential
nutrients throughout the life span. Recent studies have shown the importance of n-3 PUFAs …

Cognitive dysfunction in major depression: From assessment to novel therapies

H Atique-Ur-Rehman, JC Neill - Pharmacology & therapeutics, 2019 - Elsevier
Major depressive disorder (MDD) is a disabling disease associated with profound functional
impairment. Cognitive deficits, increasingly recognised as a core feature of MDD, reduce …